This week we see British crops destroyed after a hemp farm butts heads with the U.K. Home Office.
And following what seemed to be a very productive public meeting between CBD industry stakeholders and the U.S. Food and Drug Administration, the FDA sent another warning letter to well-known brand CuraLeaf. Then all the way in Israel, the medical cannabis export initiative has been delayed due to internal squabbles. All that and more in this week’s Cannabis Business Weekly Review and Newsletter.
In a show of force, the U.K. Home Office is demonstrating their strict rules by withdrawing the license of Hempen, an organic farm in Oxfordshire. The cultivators have been forced to destroy 40 acres of their hemp, costing the business over £200,000 in lost revenue. Hempen said that in their annual declaration they admitted to illegally producing CBD for trade in the U.K. market.
Edmonton-based Aurora announced that it was the sole winner of the Italian government’s latest contract to supply the country with medical cannabis. Aurora beat out fellow Canadian companies Tilray, Canopy, and Wayland, as well as multiple companies from different countries. Over the next two years, Aurora will supply a minimum of 400 kilogram of medical cannabis from its Canadian EU GMP certified facilities and imported to Italy through Aurora Deutschland, its wholly-owned European subsidiary, said the company.
In a warning letter dated July 22, 2019, The FDA addressed multiple violations being committed by the company CuraLeaf. Does that name sound familiar to you? It should. It’s the company that secured a deal with CVS to sell CBD products in the pharmacy chain earlier this year. In the letter, the FDA referred to CuraLeaf products as “unapproved and misbranded human drugs products.”
People were thrilled when the Israeli government approved a progressive new program to export medical cannabis to the international market. However, differences regarding who will control pricing between the officials at the Israeli Ministries of Health and Finance have delayed the recently-launched export initiative.
The Vape Industry was so quickly becoming a permanent economic fixture in the global market moving too fast to control — often mislabeled as a “fad” by talking heads. However, vaping rapidly became not only a lifesaver, but also a lifestyle — and what’s considered my most to be a healthier lifestyle.
OTHER TRENDING NEWS
LIMITED-TIME OFFER. For people who need instant relief from their pain, insomnia, or anxiety, vaping CBD can be the ultimate solution. Vaping is believed to be safer than smoking and works faster than edibles. When you come across such a high quality product as the PhenoPen, it’s a no-brainer.
While the CBD industry is growing in leaps and bounds, scientific research and studies remain lacking. One thing that nobody really has a clue about is what the right CBD dose is for which condition. For the time being, there are no specific guidelines which has patients feeling confused and frustrated.